News

There’s a long history to recognizing that social factors shape people’s health. But the social determinants of health are getting more attention than ever. Will that attention turn into action and lasting change?

Across the globe, new drugs — injections, topical and oral — are being developed to help patients with atopic dermatitis.

Research suggests that COVID-19 vaccination may serve a therapeutic effect, possibly reducing the risk of developing long COVID when administered to those currently infected.

Data suggest most patients have positive serology results a month following vaccination with either the Moderna or Pfizer vaccine.

In COVID-19 news, the FDA has approved Olumiant for new COVID-19 indication, but had limited Janssen’s COVID-19 vaccine. The agency has launched a new program for rare disease drug development and approved a new oral form of ALS therapy. Regulators have also extended the review time for both a new Pompe disease therapy and the sNDA for Myfembree for endometriosis. Additionally, Eisai has completed its submission of lecanemab for Alzheimer’s disease.

The partnership will allow international manufacturers to use the technologies for the potential development of COVID-19 vaccines, treatments and diagnostics to benefit people living in low- and middle-income countries.

Pirfenidone is used to treat patients with idiopathic pulmonary fibrosis, a progressive rare disease that make it difficult to breathe.

It is not clear whether gut inflammation has a causal role in myeloproliferative neoplasms, or the other way around.

Research and discussion about the high cancer rates among Black Americans used to be dominated by genetics and the search for biological differences. Now attention has shifted to the social determinants of health.

Price-transparency rule allows insurers to cut MLR payments by using incentives to encourage consumers to choose low-cost, high-value providers.

Multiple patents on original biologics delay when biosimilars get on the market in the US. University of Denver Sturm College of Law legal experts argue in a preprint that changes in how the original patents are written could reduce the number of duplicative patents and legal gamesmanship.

A Cleveland Clinic researcher anticipates that the FDA’s definition of strength of formulation could impair acceptance of Boehringer Ingelheim’s biosimilar to Humira (adalimumab), even though the FDA has approved the biosimilar as “interchangeable” to Humira.

Findings from phase 2 trials reported in Journal of Clinical Oncology seed hopes that winnowing out certain types of T cells from peripheral blood stem-cell transplants will make chronic graft-versus-host disease less common. Randomized trials are underway to test the proposition.

High engagement was linked with high weight loss, the analysis shows.

The administration of adult stem cells increased survival in patients with both acute and chronic graft-versus-host disease in a compassionate use program.

Safe and effective long-term treatment is important for stable disease control in atopic dermatitis.

Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail.

The FDA has approved a rare disease therapy and an additional indication for Enhertu, and grants priority review for Imfinzi in biliary tract cancer. Regulators have issued complete response letters for three therapies. The agency also has scheduled an advisory committee for Nuplazid in Alzheimer’s psychosis.

Beauty may be in the eye of the beholder, but drug price trends are in the way you crunch the numbers.

Bortezomib is part of the company’s KabiConnect program, a recent expansion of its KabiCare patient support program

Politics and policies were among the main topics at the meeting in Las Vegas. But the 6,000 attendees also heard about biosimilars, the gross-to-net price gap and the ripple effects of the CMS’ Aduhelm coverage decision.

At the 2022 Asembia Specialty Pharmacy Summit, healthcare policy experts at Avalere shared insights into the politics of a less ambitious Build Back Better bill and the healthcare provisions it might include. If a "skinny bill" doesn't get passed, the healthcare action of the Biden administration might shift to CMS Innovation Center and payment models, including a successor to the Oncology Care Model, they said.

Ryan Urgo, Managing Director, Health Policy at Avalere addressed the Biden administration’s healthcare priorities and if the Build Back Better legislation will include provisions that deal with drug prices? Urgo spoke at this year's annual Asembia Specialty Pharmacy Summit in Las Vegas on the subject, as well.

Many patients don’t fill their prescriptions because of the cost. TailorMed is a software platform that connects patients to possible sources of financial assistance.

Patients with eosinophilic esophagitis (EoE) are faced with delayed diagnosis, burdens related to symptoms, quality of life and cost, but lack targeted systemic therapies to improve long-term disease control.

Drug manufacturers are challenging the discounted drug program, but if they are blamed for the closing of rural hospitals that depend on 340B funds, the challenge may have a serious downside, warned an expert on the program.

Jayne Hornung, Chief Clinical Officer, Pharmacy, MMIT addresses the difference between digital therapeutics in the pharmacy and medical benefit space, and digs into the potential causes of the slow uptake in digital therapeutics among payers during this year's Asembia Specialty Pharmacy Summit in Las Vegas.

Doug Long, vice president of Industry Relations at IQVIA spoke on how the current inflationary trend in the economy affects healthcare spending and prices, as well as the trend of specialty drugs accounting for half of the drug spend in healthcare. Hear more of what he shared with our team at this year's Asembia Specialty Pharmacy Summit in Las Vegas.